IMF co-founders Susie and Brian Durie receive honorary doctorate from Vrije Univesiteit Brussel

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

International Myeloma Foundation co-founder and president, Susie Durie, and Chairman Brian Durie were awarded a joint honorary doctorate for scientific excellence from the Vrije Universiteit Brussel at a ceremony in Brussels.

Honorary doctorates were also bestowed upon Swedish statistician Hans Rosling (given posthumously), French mathematics historian Karine Chemla, Belgian pioneering mathematician Freddy Van Oystaeyen, American mathematician and champion of better STEM education Padmanabhan Seshaiyer, Dutch physicist and science communicator Robbert Dijkgraaf, and political cartoonist Gerard Alsteens.

The university praised what its leadership called Durie’s “extraordinary” merit: “He is at the foundation of the development of new diagnostic and therapeutic possibilities, which have led to a significant increase in life expectancy following the diagnosis of multiple myeloma.” Together with Susie Durie, they founded the IMF “to inform patients and to involve them in the knowledge about their illness, but also to encourage doctors worldwide to work together to develop best practice guidelines.”

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login